Trials / Unknown
UnknownNCT01355991
Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI
Acute and Chronic Effects of an Anticholinergic Agent or a Long-Acting Beta 2 Agonist on Levels of Exhaled Nitric Oxide and Pulmonary Function in Persons With Tetraplegia
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- James J. Peters Veterans Affairs Medical Center · Federal
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To determine the acute and chronic effects of a short course of treatment on spinal cord injured (SCI) individuals with either an anticholinergic agent (tiotropium) or with a β₂ agonist (Salmeterol) on: * Fraction of expired NO (FeNO) * Selected Biomarkers of inflammation in exhaled breath condensates (EBC) * Pulmonary function, as measured by pulmonary function tests and body plethysmography
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiotropium | 18mcg/ capsule inhaled once daily for two weeks. |
| DRUG | Salmeterol | 50mcg inhalation twice daily for two weeks |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2016-03-01
- Completion
- 2016-08-01
- First posted
- 2011-05-19
- Last updated
- 2015-10-23
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01355991. Inclusion in this directory is not an endorsement.